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Impella Versus Intra-Aortic Balloon Pump for HighRisk PCI: A Propensity-Adjusted Large-Scale Claims
Dataset Analysis
Alexandra J. Lansky, MDa,*, Daniela Tirziu, PhDa, Jeffrey W. Moses, MDb,c, Cody Pietras, BAa,
E. Magnus Ohman, MDd, William W. O’Neill, MDe, Mercedes M. Ekono, MPHf,
Cindy L. Grines, MDg, and Helen Parise, ScDa
Impella was approved by the Food and Drug Administration in 2015 for use during highrisk percutaneous coronary interventions (PCIs); however, its safety and efficacy compared with intra-aortic balloon pump (IABP) has not been evaluated in contemporary
practice and remains debated. We aimed to compare postapproval outcomes and costs of
Impella versus IABP support for high-risk PCI in real-world practice across hospitals in
the United States. We identified patients from the Premier Healthcare Database undergoing nonemergent Impella- or IABP-supported high-risk PCI. We used propensity adjustment to control baseline, procedure, and post-PCI medical treatment differences between
treatment groups. We included patients undergoing nonemergent single-PCI procedures
with either Impella or IABP support and excluded patients presenting with acute ST-elevation myocardial infarction or cardiogenic shock or requiring >1 mechanical support
devices during index hospitalization. Outcomes included in-hospital survival, myocardial
infarction (MI), cardiogenic shock, stroke, bleeding requiring transfusion, acute kidney
injury, index hospitalization length of stay, and costs. From April 2016 to June 2019, a
total of 48,179 patients were treated with Impella or IABP mechanical circulatory support
at 304 hospitals in the United States. Among these, we identified 2,156 patients undergoing
nonemergent high-risk PCI treated with Impella (n = 1,447) or IABP (n = 709). After propensity adjustment, Impella use was associated with improved survival (odds ratio [OR]
1.55, 95% confidence interval [CI] 1.02 to 2.36) and less MI (OR 0.29, 95% CI 0.18 to
0.46) and cardiogenic shock (OR 0.54, 95% CI 0.39 to 0.74). Stroke, bleeding requiring
transfusion, and acute kidney injury were similar between groups. In conclusion, this Premier Healthcare Database propensity-adjusted analysis, Impella use during nonemergent
high-risk PCI was associated with improved survival and reduced in-hospital MI and cardiogenic shock compared with IABP. © 2022 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/) (Am J Cardiol 2022;185:29−36)

Mechanical circulatory support (MCS) with the intraaortic balloon pump (IABP) or the microaxial Impella
blood pump is frequently used during high-risk percutaneous coronary interventions (PCIs) to maintain hemodynamic stability and enable complete revascularization.1,2
The Impella ventricular devices can provide up to 3.5 l/min
of cardiac output and reduce left ventricular preload and
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afterload, maintain cardiac power output, and prevent myocardial ischemia.3−10 The PROTECT II randomized trial
demonstrated that Impella 2.5 provided superior hemodynamic support compared with IABP and improved major
adverse events at 90 days in the per-protocol population
(40% with Impella vs 51% with IABP, p = 0.023).4 Based
on these results, the Food and Drug Administration
approved Impella 2.5 in 2015 and Impella CP in 2016 for
patients undergoing high-risk PCI. We aimed to evaluate
outcomes of nonemergent, mechanical supported, high-risk
PCI with IABP compared with Impella since its approval in
2016 in a real-world setting, using a large-scale claims database. Although previous registry-based studies have compared population-wide outcomes11 and acute myocardial
infarction (MI) outcomes,12 this is the first such study to
compare outcomes between Impella and IABP in patients
with high-risk PCI.
Methods
We identified patients undergoing MCS with Impella or
IABP from the Premier Healthcare Database (PHD), a
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large, real-world, hospital-based, service-level, all-payer
database, with more than 700 contributing hospitals from
all regions of the United States.13 Inpatient admissions
include over 121 million visits, with more than 10 million
annual visits since 2012, representing approximately 25%
of annual United States inpatient admissions.13 PHD contains discharge-level information on International Classification of Diseases (ICD) diagnostic codes, hospitalsubmitted Current Procedural Terminology, and Healthcare
Common Procedure Coding System codes for diagnostic
and therapeutic procedures recorded during each admission,
in addition to demographic characteristics, co-morbidities,
and medications. Hospitalization costs of all billed items,
including hospital services, medical procedures, equipment
fees, medications, diagnostics, and laboratory tests can be
determined from the PHD charge master by the costaccounting department, administrative records on length of
stay (LOS), and discharge status.
We identified patients from the PHD undergoing MCS
with Impella or IABP at 304 hospitals in the United States
after Impella approval from April 2016 to June 2019 (Supplementary Figure 1). Among those, we included only
patients undergoing nonemergent high-risk PCI, identified
by ICD Tenth Revision (ICD-10) procedure codes (Supplementary Appendix 1) and compared outcomes based on the
type of MCS device (Impella or IABP) used during PCI,
identified based on ICD-10 procedures codes (i.e.,
5A0221D, 5A0211D, 5A02210, and 5A02110) (Supplementary Appendix 1).
We included patients with nonemergent admissions
undergoing a single-PCI procedure with either Impella or
IABP support on the day of admission and excluded all
admissions coded as emergent. We excluded patients with
cardiogenic shock or ST-elevation MI (STEMI) on hospital
admission, patients undergoing more than 1 PCI procedure
during the admission, requiring multiple MCS devices during index hospitalization, or undergoing PCI and MCS on
different days. Although single-PCI procedures were
selected to exclude patients returning for PCI complications
during the same admission, this may have excluded some
high-risk procedures for left main or multivessel disease
treatment that were staged during the same hospitalization.
This likely excluded some but not most of the left main
interventions, which are customarily treated first with
MCS, and when staging is required, often it is done during
a readmission, and therefore, these patients would be
included in the population studied. The patient flowchart
with inclusion/exclusion criteria is presented in Supplementary Figure 1. All patient data for this analysis were deidentified and exempt from institutional review board approval
requirements.
The clinical outcomes of the study were in-hospital
survival, MI, cardiogenic shock, all stroke (including
ischemic and hemorrhagic stroke), intracerebral hemorrhage or transient ischemic attack, bleeding requiring
transfusion, and acute kidney injury (AKI) (codes
included in Supplementary Appendix 2) occurring during the index hospitalization at the PCI site. All clinical
outcomes were identified during the hospitalization or
discharge but were not coded “present on admission”.
The use of ICD Ninth Revision and ICD-10 codes to

identify co-morbidities and overall diagnoses in administrative datasets have been previously validated.14,15 Economic outcomes included the index hospital LOS and
aggregate costs.
A statistical analysis plan was developed a priori and the
analysis was performed by the co-authors, without external
input. We compared the clinical outcomes of patients
treated with Impella versus IABP. Chi-square or Fisher’s
exact tests and t tests were used to identify baseline differences in demographic and clinical characteristics, and standardized mean differences were calculated.
To address potential confounding, propensity scores were
created to control for differences in (1) baseline characteristics, (2) procedure characteristics, and (3) in-hospital medications between the Impella and IABP treatment cohorts. The
propensity to be treated with Impella or IABP was estimated
using logistic regression based on the following baseline characteristics: age; gender; race; marital status; region; insurer;
admission type; hospital teaching status; number of hospital
beds; and high-cost co-morbidities present on admission,
including diabetes mellitus, congestive heart failure, chronic
obstructive pulmonary disease, renal failure, hypertension,
smoking, obesity, acute respiratory failure, multivessel PCI,
and non-STEMI (NSTEMI). In addition, the propensity score
model included the following procedure characteristics: rotational atherectomy; intravascular ultrasound; transradial
access, bifurcated lesion; chronic total occlusion; and in-hospital medication use: glycoprotein IIb/IIIa inhibitors, ticagrelor, prasugrel, nonvitamin K antagonist oral anticoagulants,
and warfarin. To assess the appropriateness of the propensity
model, standardized mean differences were estimated before
and after propensity adjustment, distributions of the propensity
scores were plotted (Supplementary Figure 2), and the c-statistic of the resulting logistic regression model was calculated.
We analyzed unadjusted and propensity-adjusted outcomes during index hospitalization. The unadjusted categorical outcome variables were assessed using chi-square
or Fisher’s exact tests and summarized using odds ratios
(ORs) and 95% confidence intervals (CIs). Independentsample t tests were used to analyze unadjusted cohort differences in LOS and costs.
Adjusted outcomes were assessed using multivariable
logistic regression, whereas LOS and costs were analyzed
using linear regression. Doubly robust models were
adjusted for the propensity score estimates as well as additional selected baseline covariates present on admission
(age, gender, diabetes mellitus, smoking, obesity, multivessel PCI, congestive heart failure, chronic renal failure,
NSTEMI, and acute respiratory failure) and summarized as
adjusted ORs or adjusted mean differences, along with 95%
CIs. The method for propensity score adjustment using doubly robust propensity score-adjusted models was specified a
priori. The significance threshold was set at an alpha <0.05,
without adjustment for multiplicity. All statistical analyses
were performed using SAS Enterprise Guide 7.1 software
(SAS Institute Inc., Cary, North Carolina).
To address potential major confounding from the possible miscoding of STEMI and cardiogenic shock as “not
present on admission” when it might have been present on
admission, we performed 2 sensitivity analysis to assess the
robustness of the results by first excluding patients with
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Table 1
Demographics and baseline characteristics
Variable
Age, years
Male sex
Marital status
Married
Single
Other/unknown
Patient race
Black
Hispanic
White
Other
Unknown
Insurance payor
Medicare
Medicaid
Managed care/commercial
Self-pay/other
Admission type
Elective
Urgent
Trauma center
N/A
Hospital region
South
Northeast
Midwest
West
Hospital location
Urban
Rural
Teaching hospital
Total number of hospital beds
0-99
100-199
200-299
300-399
400-499
500+
High-cost co-morbidities
Diabetes
Congestive heart failure
COPD
Chronic renal failure
Hypertension (any)
Hypertension (essential)
Hypertension (non-essential)*
Smokingy
Obesityz
Acute respiratory failure
NSTEMI
PCI characteristics
Multivessel PCI
Single-vessel PCI
Other procedures
Right heart catheterization
Rotational atherectomy
Intravascular ultrasound
Transradial access
Bifurcation lesionx
Chronic coronary total occlusion
Mechanical ventilation

IABP n = 709

Impella n = 1,447

Standardized Difference
(Impella-IABP)

p Value

69.2§10.9
65.6%

71.4§10.9
73.3%

-0.20
-0.17

<0.0001
0.0003

59.8%
28.1%
12.1%

51.7%
39.2%
9.1%

0.24

<0.0001

6.6%
4.0%
74.6%
12.1%
2.7%

6.2%
5.0%
69.1%
17.3%
2.4%

0.16

0.022

68.4%
6.1%
20.0%
5.5%

73.0%
7.5%
15.8%
3.8%

0.15

0.012

64.9%
34.1%
0.0%
1.0%

79.8%
19.2%
0.1%
0.9%

0.35

<0.0001

32.2%
31.0%
24.1%
12.7%

40.9%
22.2%
21.3%
15.6%

0.25

<0.0001

92.4%
7.6%
61.5%

92.5%
7.5%
60.2%

-0.0031

0.93

0.027

0.57

1.1%
3.1%
9.9%
18.6%
13.7%
53.6%

1.1%
6.2%
7.8%
16.7%
15.3%
52.9%

0.17

0.024

40.5%
34.1%
16.9%
6.9%
88.3%
44.9%
44.2%
15.0%
20.2%
7.6%
32.6%

41.6%
60.9%
17.1%
5.9%
88.1%
29.8%
59.2%
13.1%
13.6%
3.8%
14.1%

-0.023
-0.56
-0.0057
0.042
0.0056
0.32
-0.31
0.054
0.18
0.165
0.45

0.64
<0.0001
0.95
0.34
0.94
<0.0001
<0.0001
0.23
0.0001
0.0002
<0.0001

29.2%
70.8%

57.2%
42.9%

0.59

<0.0001

3.2%
4.8%
17.2%
12.4%
0.6%
14.3%
20.2%

4.4%
7.1%
25.2%
10.6%
0.2%
21.7%
8.2%

-0.061
-0.098
-0.20
0.058
0.058
-0.20
0.35

0.20
0.039
<0.0001
0.22
0.23
<0.0001
<0.0001
(continued)
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Table 1 (Continued)
Variable

IABP n = 709

Impella n = 1,447

Standardized Difference
(Impella-IABP)

p Value

26.4%
37.4%
6.4%
7.2%
6.4%

6.5%
36.8%
5.6%
7.3%
3.3%

0.56
0.011
0.032
-0.0024
0.15

<0.0001
0.81
0.49
1.00
0.001

Medications
Glycoprotein IIb/IIIa inhibitor
Ticagrelor
Prasugrel
Novel oral anticoagulant
Warfarin

COPD = chronic obstructive pulmonary disease; IABP = intra-aortic balloon pump; NSTEMI = non−STsegment elevation myocardial infarction;
PCI = percutaneous coronary intervention.
Values are mean § SD or %. Standardized mean differences were estimated before and after propensity score adjustment.
*Nonessential hypertension includes hypertension with heart disease, hypertension with chronic kidney disease, and secondary hypertension diagnoses.
y
Smoking includes nicotine dependence, uncomplicated or with withdrawal or in remission (codes in Supplementary Appendix 3).
z
Obesity includes obesity, severe obesity, and overweight (codes in Supplementary Appendix 3).
x
Reported bifurcation lesions exclude left main interventions.

STEMI and the second, removing both STEMI and cardiogenic shock. The intent of these sensitivity analyses was to
evaluate outcomes by treatment group by eliminating
STEMI and/or cardiogenic shock as potential major confounders if miscoded as postprocedure complications rather
than diagnoses present on admission (both exclusion criteria for our high-risk PCI population).
To assess predictors of in-hospital mortality, we performed a multivariable logistic regression analysis that
included patient characteristics, outcomes, and treatment
group in the propensity-adjusted population.
The sponsor of the study had no role in data collection,
data analysis, data interpretation, writing the manuscript, or
the decision to submit the manuscript. The authors had full
access to all the data in the study and all co-authors
reviewed the manuscript and provided input, vouched for
the accuracy of the data, and agreed to submit the manuscript for publication.

Results
From April 2016 to June 2019, a total of 48,179 patients
were treated with Impella or IABP MCS at 304 hospitals in
the United States; among these, we identified 2,156 patients
undergoing nonemergent high-risk PCI, including 1,447
patients (67.1%) treated with Impella and 709 patients
(32.9%) treated with IABP (Supplementary Figure 1).
Baseline demographics and clinical characteristics (codes
included in Supplementary Appendix 3) are presented in
Table 1. Before adjustment, Impella patients were older,
more likely to be male, with Medicare insurance, had more
congestive heart failure, multivessel PCI, and chronic coronary total occlusion than patients with IABP. Patients with
IABP were more obese, had more acute respiratory failure,
NSTEMI at presentation, single-vessel PCI, and glycoprotein IIb/IIIa inhibitor and warfarin use (Table 1). Standardized mean differences estimated before and after propensity
adjustment, along with distributions of the propensity
scores are presented in Supplementary Figure 2. Differences between treatments were controlled after propensity

Table 2
Unadjusted and adjusted in-hospital clinical outcomes: Impella versus IABP
Clinical Outcomes

Survival
Myocardial infarction
STEMI
NSTEMI
Cardiogenic shock
Stroke
Bleeding requiring transfusion
Acute kidney injury

Unadjusted

Adjusted

IABP n = 709

Impella n = 1,447

Odds Ratio (95% CI)

p Value

Odds Ratio (95% CI)

p Value

91.0%
11.9%
8.2%
5.4%
18.9%
2.3%
2.3%
1.6%

95.3%
2.5%
1.4%
1.3%
8.3%
1.7%
2.5%
1.6%

2.01 (1.41, 2.87)
0.19 (0.13, 0.28)
0.16 (0.09, 0.26)
0.23 (0.12, 0.43)
0.39 (0.30, 0.51)
0.73 (0.39, 1.38)
1.11 (0.61, 2.01)
1.02 (0.50, 2.11)

0.0002
<0.0001
<0.0001
<0.0001
<0.0001
0.40
0.88
1.00

1.55 (1.02, 2.36)
0.29 (0.18, 0.46)
0.28 (0.15, 0.50)
0.33 (0.16, 0.72)
0.54 (0.39, 0.74)
0.98 (0.46, 2.11)
1.18 (0.59, 2.37)
0.89 (0.39, 2.05)

0.042
<0.0001
<0.0001
0.0500
0.0001
0.96
0.65
0.78

IABP = intra-aortic balloon pump; MI = myocardial infarction; NSTEMI = non−ST-segment elevation myocardial infarction; STEMI = ST-segment elevation myocardial infarction.
Unadjusted outcomes were assessed using chi-square or Fisher’s exact tests and presented using odds ratios and 95% CIs. Adjusted outcomes were
assessed using multivariable logistic regression. Doubly robust models adjusted for the propensity score estimates as well as additional selected baseline
covariates present on admission. The resulting adjusted odds ratios along with 95% CI are presented. The significance threshold was set at an alpha <0.05
without adjustment for multiplicity.
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Table 3
Sensitivity analyses of in-hospital clinical outcomes
1. Removing STEMI
Clinical Outcomes

Survival
NSTEMI
Cardiogenic shock
Stroke
Bleeding requiring transfusion
Acute kidney injury

Unadjusted

Adjusted

IABP n = 651

Impella n = 1,427

Odds Ratio(95% CI)

p Value

Odds Ratio(95% CI)

p Value

92.0%
6.1%
16.4%
2.0%
2.0%
1.7%

95.9%
1.3%
7.5%
1.7%
2.3%
1.5%

2.05 (1.39, 3.02)
0.20 (1.08, 0.38)
0.41 (0.31, 0.55)
0.84 (0.43, 1.66)
1.16 (0.61, 2.22)
0.91 (0.44, 1.89)

0.0003
<0.0001
<0.0001
0.61
0.65
0.80

1.49 (0.94, 2.36)
0.31 (0.15, 0.67)
0.53 (0.38, 0.75)
1.22 (0.54, 2.76)
1.21 (0.57, 2.56)
0.84 (0.36, 1.94)

0.090
0.0028
0.0003
0.63
0.62
0.68

2. Removing STEMI or Cardiogenic Shock
Clinical Outcomes

Survival
NSTEMI
Stroke
Bleeding requiring transfusion
Acute kidney injury

Unadjusted

Adjusted

IABPn = 544

Impella n = 1,320

Odds Ratio(95% CI)

p Value

Odds Ratio(95% CI)

p Value

94.3%
5.3%
1.7%
1.8%
1.5%

98.4%
0.6%
1.3%
1.3%
1.4%

3.74 (2.13, 6.57)
0.11 (0.05, 0.27)
0.78 (0.34, 1.75)
0.70 (0.32, 1.53)
0.93 (0.40, 2.14)

<0.0001
<0.0001
0.54
0.37
0.86

3.21 (1.62, 6.36)
0.17 (0.06, 0.48)
0.94 (0.34, 2.59)
0.96 (0.36, 2.51)
0.89 (0.33, 2.37)

0.0009
0.0010
0.91
0.93
0.81

Statistical analyses were performed as presented in Table 2. Abbreviations as in Table 2.

adjustment. The c-statistic for the propensity model was
0.824, indicating excellent discriminatory ability.
The unadjusted in-hospital survival rate was significantly
higher with Impella than the IABP (95.3% vs 91.0%; OR
2.01, 95% CI 1.41 to 2.87) (Table 2). Unadjusted rates of
subsequent MI and cardiogenic shock were significantly
lower with Impella than the IABP (Table 2). There were no
significant differences between groups in the rates of stroke,
bleeding, or AKI. After adjustment, patients with Impella
had improved survival (OR 1.55, 95% CI 1.02 to 2.36) and
lower rates of MI (OR 0.29, 95% CI 0.18 to 0.46) and cardiogenic shock (OR 0.54, 95% CI 0.39 to 0.74) than IABP
(Table 2). There were no differences in the adjusted odds of
stroke, bleeding requiring transfusion, or AKI between the
treatment groups; however, the odds of experiencing AKI
in the Impella group was lower after risk adjustment than
the unadjusted model (0.89 vs 1.02) (Table 2).
The first sensitivity analysis removed patients with
STEMI for possible miscoding as being absent on admission (Supplementary Figure 3). Results remained consistent
with greater unadjusted survival rate with Impella than with
IABP (95.9% vs 92.0%, p = 0.0003), as well as improved
rates of NSTEMI and cardiogenic shock (p <0.0001)
(Table 3). There were no differences in stroke, bleeding, or
AKI between groups. After adjustment, the survival benefit
was no longer significant with Impella (OR 1.49, 95% CI
0.94 to 2.36, p = 0.090), whereas the benefit in reducing
NSTEMI and cardiogenic shock rates remained significant
(Table 3).
We performed a second sensitivity analysis that removed
patients with STEMI or cardiogenic shock as possibly miscoded as a complication rather than present on admission
(Supplementary Figure 3). Results remained consistent,
favoring greater survival (unadjusted rates: 98.4% vs
94.3%; adjusted OR 3.21, 95% CI 1.62 to 6.36) and less
NSTEMI (unadjusted rates: 0.6% vs 5.3%; adjusted OR
0.17, 95% CI 0.06 to 0.48) in the Impella group (Table 3).

There were no significant differences in the rates of stroke,
bleeding, or AKI between groups.
Hospital LOS was significantly shorter by approximately
2.4 days with Impella in the unadjusted population
(3.1 days with Impella vs 5.5 days with IABP), a difference
that was attenuated to approximately 1.4 days but remained
significant after adjustment (3.4 days with Impella vs
4.8 days with IABP). Overall, the average unadjusted index
hospitalization costs with Impella were 27% higher than
with IABP and 37% higher in the adjusted population
(Table 4). For surviving patients, Impella costs were 43%
higher ($47,541 with Impella vs $33,240 IABP, p <0.0001)
in the adjusted population. LOS and index hospital costs
were consistent in both sensitivity analyses (Supplementary
Table 1).
Univariate analyses are presented in Supplementary
Table 2. Multivariable logistic regression of the primary
propensity-adjusted population identified the following inhospital complications as predictors of in-hospital mortality: MI, cardiogenic shock, stroke, and bleeding requiring
transfusion. Developing cardiogenic shock after PCI was
the strongest predictor of in-hospital mortality (OR 7.54,
95% CI 4.97 to 11.45) (Figure 1).
Discussion
This propensity-adjusted, population-based analysis of
patients undergoing nonemergent MCS supported high-risk
PCI suggests that Impella support is associated with a 55%
improvement in survival, a 71% reduction in MI, and a
46% reduction in cardiogenic shock, with no observed difference in the rate of stroke, bleeding requiring transfusion,
or AKI. Sensitivity analyses designed to evaluate the
robustness of the data and eliminate major confounding
from possible coding errors largely mirrored the trends
observed in the overall population. Patients treated with
Impella-supported high-risk PCI had better in-hospital
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Table 4
Unadjusted and adjusted economic outcomes: Impella versus IABP
Economic Outcomes

Unadjusted
IABP
n = 709

Impella
n = 1,447

Adjusted

Difference (%)

p Value

IABP
n = 709

LOS/Costs (All Patients)
Index LOS, mean
Index LOS, median (Q1, Q3)
Index costs, mean
Index costs, standard deviation

5.5
4.0 (2.0, 7.0)
$37,625
$32,230

3.1
2.0 (1.0, 3.0)
$47,819
$28,795

5.3
4.0 (2.0, 7.0)
$34,889
$25,620

3.0
1.0 (1.0, 3.0)
$46,770
$27,751

Difference (%)

p Value

LOS/Costs (All Patients)
-44.34%

<0.0001

27.10%
-10.66%

<0.0001
—

4.8
4.8 (4.6, 5.0)
$35,655
$32,267

LOS/Costs (Surviving Patients)
Index LOS, mean
Index LOS, median (Q1, Q3)
Index costs, mean
Index costs, standard deviation

Impella
n = 1,447

3.4
3.4 (3.3, 3.5)
$48,784
$28,801

-29.11%

<0.0001

36.82%
-10.74%

<0.0001
—

LOS/Costs Surviving Patients)
-43.59%

<0.0001

34.05%
8.32%

<0.0001
—

4.5
4.4 (4.3, 4.7)
$33,240
$25,340

3.3
3.3 (3.2, 3.4)
$47,541
$27,721

-25.77%

<0.0001

43.02%
9.40%

<0.0001
—

LOS = length of stay (day).
Unadjusted outcomes were assessed using independent-sample t tests. Adjusted outcomes were analyzed using linear regression model.

survival and outcomes and shorter LOS at the expense of
higher average index hospital costs compared with IABP.
Developing cardiogenic shock after PCI was the strongest
predictor of in-hospital mortality.
The benefits of stabilizing hemodynamics with MCS
devices during “high-risk” PCI are to prevent hemodynamic
collapse, enable optimal revascularization, and improve
clinical outcomes. The PROTECT II trial demonstrated a
reduction in the rates of death, stroke, MI, or the composite
of death/stroke/MI at 90 days with Impella 2.5 compared
with IABP among patients who received the intended MCS
device (per protocol).4 In a post hoc multivariable analysis,

Impella use was an independent predictor of freedom from
major adverse events (OR 0.75, 95% CI 0.61 to 0.92) and
major adverse cardiac and cerebral events (OR 0.76, 95%
CI 0.61 to 0.96) at 90 days after the procedure.16 These benefits extended to patients achieving complete revascularization.17 Our findings in a contemporary “real-world”
population are consistent with and extend the PROTECT II
trial results.
Our results, however, contrast recently published largescale studies of Impella use for broad indications, including
STEMI, cardiogenic shock, and high-risk PCI, and in acute
MI that reported worse in-hospital outcomes with Impella

Figure 1. Predictors of in-hospital mortality. Forest plot of multivariable logistic regression analysis of the propensity-adjusted population demonstrating the contribution of in-hospital complications to mortality. Patient characteristics are on admission. For age, the OR corresponds to a 1-year increase in patient age.
LCL = lower confidence limit; UCL = upper confidence limit.
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than IABP.11,12 Notable differences in reported outcomes of
the previous study using the same PHD maybe due to (1)
the undifferentiated population studied, (2) inclusion of
patients from a time period that preceded Impella approval
(2004 to 2016), impacting patient complexity, and (3) confounding resulting from the broad spectrum of clinical presentations included in the study population.11 In contrast,
our aim was to use the PHD to represent real-world practice
focused on a single clinical indication (high-risk PCI), in a
timeframe limited to Food and Drug Administrationapproved indication of Impella, using propensity-adjusted
methodology and sensitivity analyses to address confounders and possible inherent miscoding of claims data. In this
more narrowly defined context, our results suggest the benefit of Impella use compared with IABP for high-risk PCI
indication.
Potential mechanisms of the benefit of Impella are the
reduction of in-hospital cardiogenic shock with Impella
compared with IABP, which was the strongest identified
predictor of mortality in our study. In addition, our analysis
did not identify an increased risk of stroke or bleeding
requiring transfusion with Impella compared with IABP.
Our data align with a recent meta-analysis, showing no
added bleeding risk with percutaneous ventricular assist
devices compared with IABP.18 Improvements in bleeding
rates in our study are consistent with recent series of largebore access devices, where ultrasound-guided access techniques have become the norm in contemporary practice (as
seen in transcatheter aortic valve replacement), reducing
vascular complications. These findings are relevant due to
the strong contribution of stroke and bleeding to in-hospital
mortality, with stroke conferring an approximately 6-fold
mortality risk and bleeding an approximately 3-fold higher
mortality risk based on our study. Therefore, careful reevaluation of contemporary interventional practice, including use of large-bore MCS, is warranted with the rapid evolution of clinical practice and interventional techniques.
Although Impella use reduced index LOS, index hospitalization costs remained higher with Impella, as was previously shown using PHD11 and in the PROTECT II costeffectiveness study ($47,667 with Impella vs $33,684 with
IABP, p <0.001).19 However, because readmission LOS
and costs were lower for Impella, after 90 days, the total
hospital charges were similar for Impella and IABP
($172,564 vs $172,758, respectively, p = 0.785), suggesting
that the initial cost differential may be offset at 90 days,
based on improved readmission LOS and less use of critical
care admissions.19
Our study should be interpreted in the context of the
inherent limitations of large claims datasets designed for
the purpose of billing rather than for assessing comparative
effectiveness of treatment strategies and the selection criteria for the population. The selection criteria for “high-risk
PCI” and the decision to use MCS and the type were determined by the treating physician, limiting our ability to specifically define the criteria for high-risk PCI. Other inherent
limitations include coding inconsistencies across providers,
lack of detailed diagnosis, timing, and indication for
Impella/IABP use (planned or bailout), potential access site
or aortoiliac disease, coronary or peripheral disease severity
characterization, hemodynamic data, or frailty, and limited
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physiologic measurement and other relevant information,
many of which can contribute to possible bias in the selection of IABP versus Impella and unmeasured confounding.
We limited our population to those undergoing single-PCI
procedures to exclude PCI complications during the same
admission; this unavoidably excluded some (but not all)
high-risk patients with left main or multivessel disease
treatment that were staged during the same hospitalization.
The matching process against a benchmark of high-risk
patients treated with Impella resulted in a selective and
smaller sample of patients treated with IABP. Although the
present study featured rigorous methods and doubly robust
analyses to lessen the impact of these limitations, these do
not eliminate the potential for remaining unmeasured confounders; therefore, this study should be interpreted in the
context of these inherent limitations.
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